379 related articles for article (PubMed ID: 11326821)
1. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area.
Badri M; Ehrlich R; Wood R; Pulerwitz T; Maartens G
Int J Tuberc Lung Dis; 2001 Mar; 5(3):225-32. PubMed ID: 11326821
[TBL] [Abstract][Full Text] [Related]
2. Impact of tuberculosis on the course of HIV-infected patients with a high initial CD4 lymphocyte count.
Mañas E; Pulido F; Peña JM; Rubio R; Gonzalez-García J; Costa R; Pérez-Rodríguez E; Del Palacio A
Int J Tuberc Lung Dis; 2004 Apr; 8(4):451-7. PubMed ID: 15141738
[TBL] [Abstract][Full Text] [Related]
3. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
4. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
5. HIV-associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death.
Kingkaew N; Sangtong B; Amnuaiphon W; Jongpaibulpatana J; Mankatittham W; Akksilp S; Sirinak C; Nateniyom S; Burapat C; Kittikraisak W; Monkongdee P; Varma JK
Int J Infect Dis; 2009 Nov; 13(6):722-9. PubMed ID: 19196530
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 co-infection in children hospitalised with tuberculosis in South Africa.
Madhi SA; Huebner RE; Doedens L; Aduc T; Wesley D; Cooper PA
Int J Tuberc Lung Dis; 2000 May; 4(5):448-54. PubMed ID: 10815739
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan.
Seyler C; Toure S; Messou E; Bonard D; Gabillard D; Anglaret X
Am J Respir Crit Care Med; 2005 Jul; 172(1):123-7. PubMed ID: 15805184
[TBL] [Abstract][Full Text] [Related]
8. The V118I mutation as a marker of advanced HIV infection and disease progression.
Zaccarelli M; Tozzi V; Lorenzini P; Forbici F; Narciso P; Ceccherini-Silberstein F; Trotta MP; Bertoli A; Liuzzi G; Marconi P; Mosti S; Perno CF; Antinori A
Antivir Ther; 2007; 12(2):163-8. PubMed ID: 17503658
[TBL] [Abstract][Full Text] [Related]
9. Incidence of tuberculosis in HIV-infected patients receiving HAART: interaction between TST and CD4 count.
Martín-Echevarria E; Rodríguez-Zapata M; Torralba M; Fernández JM; Moreno A; Casado JL; Dronda F; Pérez-Elías MJ; Navas E; Moreno S
Int J Tuberc Lung Dis; 2011 Oct; 15(10):1347-52. PubMed ID: 22283893
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
[TBL] [Abstract][Full Text] [Related]
11. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
12. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
El Amari EB; Toutous-Trellu L; Gayet-Ageron A; Baumann M; Cathomas G; Steffen I; Erb P; Mueller NJ; Furrer H; Cavassini M; Vernazza P; Hirsch HH; Bernasconi E; Hirschel B;
AIDS; 2008 May; 22(9):1019-28. PubMed ID: 18520345
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of HIV-infected tuberculosis patients in Thailand.
Mankatittham W; Likanonsakul S; Thawornwan U; Kongsanan P; Kittikraisak W; Burapat C; Akksilp S; Sattayawuthipong W; Srinak C; Nateniyom S; Tasaneeyapan T; Varma JK
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):93-103. PubMed ID: 19323040
[TBL] [Abstract][Full Text] [Related]
14. Early participation in an HIV cohort study slows disease progression and improves survival. The Swiss HIV Cohort Study.
Battegay M; Wirz M; Steuerwald MH; Egger M
J Intern Med; 1998 Dec; 244(6):479-87. PubMed ID: 9893101
[TBL] [Abstract][Full Text] [Related]
15. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
16. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.
Hershow RC; O'Driscoll PT; Handelsman E; Pitt J; Hillyer G; Serchuck L; Lu M; Chen KT; Yawetz S; Pacheco S; Davenny K; Adeniyi-Jones S; Thomas DL
Clin Infect Dis; 2005 Mar; 40(6):859-67. PubMed ID: 15736020
[TBL] [Abstract][Full Text] [Related]
18. Survival in a cohort of human immunodeficiency virus-infected tuberculosis patients in New York City. Implications for the expansion of the AIDS case definition.
Stoneburner R; Laroche E; Prevots R; Singh T; Blum S; Terry P; Reatrice S; Adler J
Arch Intern Med; 1992 Oct; 152(10):2033-7. PubMed ID: 1358042
[TBL] [Abstract][Full Text] [Related]
19. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J;
J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
